1. Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal Cancer.
- Author
-
Chan, K. C. Allen, Lam, W. K. Jacky, King, Ann, Lin, Vivien S., Lee, Patrick P. H., Zee, Benny C. Y., Chan, Stephen L., Tse, Irene O. L., Tsang, Amy F. C., J. Li, Maggie Z., Peiyong Jiang, Ai, Qi Yong H., Poon, Darren M. C., Au, K. H., Hui, Edwin P., Ma, Brigette B. Y., Van Hasselt, Andrew C., Chan, Anthony T. C., Woo, John K. S., and Lo, Y. M. Dennis
- Subjects
DNA ,CONFIDENCE intervals ,BLOOD plasma ,ENDOSCOPIC surgery ,EARLY detection of cancer ,MAGNETIC resonance imaging ,RISK assessment ,NOSE ,COMPARATIVE studies ,DESCRIPTIVE statistics ,CHI-squared test ,PROGRESSION-free survival ,EPSTEIN-Barr virus diseases ,NASOPHARYNX tumors ,LONGITUDINAL method ,ENDOSCOPY ,DISEASE risk factors ,DISEASE complications - Abstract
We previously conducted a prospective study to show that nasopharyngeal cancer (NPC) screening with circulating Epstein-Barr virus (EBV) DNA analysis can improve survival. However, the long-term significance of positive results in individuals without cancer was unclear. We conducted a second-round screening at a median of 43 months after the initial screening. Participants with detectable plasma EBV DNA were retested in 4 weeks, and those with persistently positive results were investigated with nasal endoscopy and magnetic resonance imaging. Of the 20,174 volunteers who participated in the first-round screening, 17,838 (88.6%) were rescreened. Among them, 423 (2.37%) had persistently detectable plasma EBV DNA. Twenty-four patients were identified as having NPC. A significantly higher proportion of patients had stage I/II cancer than in a historical cohort (67% vs. 20%; chi-square test, P<0.001), and they had superior 3-year progression-free survival (100% vs. 78.8%). Compared with participants with undetectable plasma EBV DNA in the first round of screening, participants with transiently and persistently positive results in the first round were more likely to have a cancer identified in the second round, with relative risks of 4.4 (95% confidence interval, 1.3 to 15.0) and 16.8 (95% confidence interval, 5.7 to 49.6), respectively. Individuals with detectable plasma EBV DNA but without an immediately identifiable NPC were more likely to have the cancer identified in another round of screening performed 3 to 5 years later. (Funded by Kadoorie Charitable Foundation and others; ClinicalTrials.gov number, NCT02063399.) [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF